RWJ-394,674

RWJ-394,674

Legal status
Legal status	In general: legal
Identifiers
IUPAC name N,N-diethyl-4-((8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl)benzamide
PubChem CID	10205965
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C33H38N2O
Molar mass	478.667 g/mol
3D model (JSmol)	Interactive image
SMILES c5ccccc5CCN1C(C4)CCC1CC4=C(c3ccc(cc3)C(=O)N(CC)CC)c2ccccc2

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

RWJ-394,674 is a drug which is used in scientific research. It is a potent, orally active analgesic drug, which produces little respiratory depression. RWJ-394,674 itself is a potent and selective agonist for δ-opioid receptors, with a Ki of 0.24nM at δ and 72nM at μ. However once inside the body, RWJ-394,674 is dealkylated to its monodesethyl metabolite RWJ-413,216 which is a potent agonist at the μ-opioid receptor and has less affinity for δ (Ki 0.26nM at μ, 46.7nM at δ). The effect of RWJ-394,674 when administered in vivo thus produces potent agonist effects at both μ and δ receptors through the combined actions of the parent drug and its active metabolite, with the δ-agonist effects counteracting the respiratory depression from the μ-opioid effects, and the only prominent side effect being sedation.